.Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BG06_Nefopam.Nefopam_1 .Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BG06_Nefopam.Nefopam_1| name: | Nefopam_1 |
| ATC code: | N02BG06_1 | route: | intravenous |
| n-compartments | 2 |
Nefopam is a centrally-acting non-opioid analgesic used for the relief of moderate to severe pain. It is unrelated chemically to NSAIDs or opioids and acts by inhibiting the reuptake of serotonin, norepinephrine, and dopamine. Nefopam is used in some countries for acute and chronic pain management but is not approved in the United States.
Pharmacokinetics after single intravenous bolus in healthy adults.
Djerada, Z, et al., & Malinovsky, JM (2014). Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. British journal of clinical pharmacology 77(6) 1027–1038. DOI:10.1111/bcp.12291 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24252055
Mimoz, O, et al., & Levy, RH (2010). Nefopam pharmacokinetics in patients with end-stage renal disease. Anesthesia and analgesia 111(5) 1146–1153. DOI:10.1213/ANE.0b013e3181f33488 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20971961
Mittur, A (2018). A Simultaneous Mixed-Effects Pharmacokinetic Model for Nefopam, N-desmethylnefopam, and Nefopam N-Oxide in Human Plasma and Urine. European journal of drug metabolism and pharmacokinetics 43(4) 391–404. DOI:10.1007/s13318-017-0457-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29305813